| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.1002/CNCR.30273 |
| P698 | PubMed publication ID | 27526184 |
| P2093 | author name string | R Donald Harvey | |
| Tyler J Beardslee | |||
| P2860 | cites work | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 |
| Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. | Q27852806 | ||
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Q27853158 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations | Q33945734 | ||
| "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. | Q35570245 | ||
| Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers | Q37155636 | ||
| Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). | Q37709570 | ||
| Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions | Q38229948 | ||
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
| Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets | Q38845845 | ||
| Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development | Q38927992 | ||
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
| Therapeutic drug monitoring in cancer--are we missing a trick? | Q44939091 | ||
| An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib | Q47872073 | ||
| The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects | Q54381356 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2016-08-15 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Precision, accuracy, and resolution-Dose selection of oral anticancer agents |
Search more.